High-dose cyclophosphamide carmustine autologous peripheral stem cell transplantation patients relapsed Hodgkin disease Between February March patients relapsed Hodgkin disease high-dose cyclophosphamide carmustine CBV autologous peripheral stem cell transplantation PSCT autologous bone marrow transplantation ABMT patient marrow abnormality hypocellularity tumor involvement cells/kg patient weight peripheral blood patient CBV administration patients early death days PSCT actuarial event-free survival patients years good relapsed Hodgkin disease patients CBV ABMT patients marrow time PSC actuarial event-free survival patients marrow metastases different actuarial event-free survival CBV PSCT patients relapsed Hodgkin diseases hypocellularity traditional harvest sites histopathologic evidence BM metastases long-term event-free survival 